news
Subpoena for Ranbaxy’s Toansa Plant
7 April 2014 | By Daiichi Sankyo
Attached is the statement of Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo Company, Limited, which was issued on April 7th, 2014...
List view / Grid view
Daiichi Sankyo
news
Daiichi Sankyo and UC San Francisco announce collaboration in drug discovery research for neurodegenerative diseases
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...
news
Daiichi Sankyo initiates phase 3 ENSURE-AF study, investigating once-daily edoxaban in patients with atrial fibrillation undergoing cardioversion
1 April 2014 | By Daiichi Sankyo Company
First patient enrolled in largest planned phase 3 study evaluating a novel oral antico-agulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion...
news
Daiichi Sankyo to facilitate new Drug Discovery in 2014 through Collaborative Research and Grants
25 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project for 2014...
news
Once-daily edoxaban evaluated in two subgroup analyses of East Asian patients from the largest comparative phase 3 trials of a novel oral anticoagulant
24 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies...
news
Daiichi Sankyo receives approval in Japan for manufacturing and marketing of the antiplatelet agent Efient® 3.75mg/5mg tablets
24 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has received approval from the Ministry of Health, Labour and Welfare in Japan for the antiplatelet agent Efient® 3.75mg/5mg Tablets...
news
Astellas Pharma and Daiichi Sankyo form compound library sharing partnership
19 March 2014 | By Daiichi Sankyo Company
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
news
Announcement regarding the project of H5N1 influenza vaccines
7 March 2014 | By Daiichi Sankyo Company
Daiichi Sankyo Company, Limited announced in August 2011 that the group company Kitasato Daiichi Sankyo Vaccine Company, Limited was selected for the Japanese Ministry of Health, Labour and Welfare's cell culture vaccine production facility capacity building grant...
news
Daiichi Sankyo and UMN Pharma enter into collaborative research agreement for Norovirus Vaccine
14 February 2014 | By Daiichi Sankyo Company
Norovirus is one of the leading causes of infectious gastroenteritis and the number of infected people reported is increasing both in Japan and globally...
news
Update on Regarding the Import Alert on Ranbaxy’s Toansa Plant
24 January 2014 | By Daiichi Sankyo Company
Ranbaxy Laboratories Limited announced that the US FDA notified the company that it is prohibited from manufacturing and distributing active pharmaceutical ingredients from its facility in Toansa, India, for FDA-regulated drug products...
news
Regarding the import alert on Ranbaxy’s Toansa Plant
24 January 2014 | By Daiichi Sankyo
Daiichi Sankyo Company Ltd. announced that the US Food and Drug Administration has issued an import alert on January 23 on Active Pharmaceutical Ingredients...
news
Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
news
Daiichi Sankyo, Virtici and Celdara Medical announce collaboration to identify and progress high potential therapeutics
8 January 2014 | By Daiichi Sankyo
Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets...
news
Daiichi Sankyo submits edoxaban Marketing Authorisation Application to the EMA for once-daily use for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism
8 January 2014 | By Daiichi Sankyo
Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation...
news
Daiichi Sankyo receives approval for additional indication of anticancer agent Topotecin® injection
23 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo Company has received supplemental new drug application (sNDA) approval for Topotecin® injection 40 mg and 100 mg (irinotecan hydrochloride hydrate) for unresectable pancreatic cancer.
